Biography

Gregory Behar (Born 1969, Swiss citizen) has served as a non‑executive member of the Board of Directors of Sonova Holding AG since 2021.

Since January 2024, Gregory Behar has been Chief Executive Officer of Recipharm AB, a contract development and manufacturing organization (CDMO) in the pharmaceutical industry. Prior to this, he served as Chief Executive Officer of Nestlé Health Science from 2014 until 31 December 2023 and became a member of the Nestlé Executive Board in 2017. From 2011 to 2014, he was President and Chief Executive Officer of Boehringer Ingelheim Pharmaceuticals Inc. (USA).

Earlier in his career, he held various leadership positions at Boehringer Ingelheim GmbH (Germany), Novartis AG and Nestlé SA. Gregory Behar holds an MBA from INSEAD, France, a Master of Science in Mechanical Engineering and Manufacturing from EPFL Lausanne, Switzerland, and a Bachelor of Science in Mechanical Engineering from the University of California, Los Angeles, USA.

Committee Memberships

He is a member of the Technology and Innovation Committee and the Nomination and Compensation Committee. 

Outside mandates

Listed companies: 

• n.a.

Other mandates:

• CEO of Recipharm AB
• Member of the Board of Directors of Amazentis SA
• Member of the Board of Directors of New Biologix (mandate held at the direction of Recipharm AB as part of his role as its CEO and thus, shall not be considered as an additional outside mandate)

Holdings as per 31.03.2025

• Shares: 2,563
• Restricted Shares¹⁾: 2,238

1) These shares are subject to a restriction period which varies from June 1, 2025 to June 1, 2030 depending on the grant date. For further details see also Note 7.4 in the consolidated financial statements.